WALTHAM, Mass., August 26, 2015 – Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing entinostat as a combination therapy in
multiple cancer indications, announced today that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the safety, tolerability and preliminary
efficacy of Syndax’s entinostat, an oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)), in combination with
Genentech’s atezolizumab (MPDL3280A), a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1), in patients with triple-negative breast cancer.
Triple-negative breast cancer is estimated to account for 10-20% of all diagnosed breast cancers and is characterized by a lack of expression of estrogen receptor (ER-), progesterone
receptor (PR-) and HER2 (HER2-) on the breast cancer cells.
SYNDAX ENTERS CLINICAL TRIAL COLLABORATION IN CANCER IMMUNOTHERAPY COMBINING ENTINOSTAT AND ATEZOLIZUMAB
SYNDAX RAISES $80 MILLION IN SERIES C FINANCING
WALTHAM, Mass., August 24, 2015 – Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer
indications, announced today that it has completed an $80 million Series C financing. The financing was led by Fidelity Management & Research Company and Delos Capital Fund LP
with participation from EcoR1 Capital, OrbiMed, Jennison Associates (on behalf of certain clients), Tavistock Life Sciences, Arrowpoint Partners, Cormorant Asset Management, BioMed
Ventures and undisclosed top-tier mutual funds, as well as existing investors Domain Associates, MPM Capital, RusnanoMedInvest (RMI) and Forward Ventures.
IlluminOss Medical Appoints Clive Ridgwell as Vice President of Sales
East Providence, RI July 21, 2015 – IlluminOss Medical, a commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced the appointment of Clive V. Ridgwell as vice president of sales. Ridgwell brings more than 30 years of commercial experience in medical device fields which he will apply to the further development of IlluminOss' product strategy in global markets.
Liquidia Technologies Names Robert A. Lippe Chief Operations Officer
RESEARCH TRIANGLE PARK, NC July 14, 2015 – Liquidia Technologies today announced it has named Robert A. Lippe as the Company’s Chief Operations Officer, effective immediately. Mr. Lippe has responsibility for manufacturing research, process development, operations, quality control and compliance and will be a key member of the senior management team.
Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury
MONTREAL, July 7, 2015 – Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, announced the completion of enrollment in its Phase 2 clinical study of THR-184 for the prevention of acute kidney injury (AKI) in “at risk” patients undergoing cardiac surgery. Results from the 452-patient study are expected by January 2016.
Afferent Pharmaceuticals Raises $55 Million in Oversubscribed Crossover Financing
SAN MATEO, Calif.—July 8, 2015 – Afferent Pharmaceuticals, a leader in the development of novel small molecule drugs for the treatment of neurogenic respiratory, urologic and pain disorders, today announced the completion of a $55 million Series C financing. The proceeds will fund the advancement of the company’s first-in-class drug candidate AF-219 for the treatment of pathologic cough, including for cough in IPF patients, as well as advancement of its next candidate compound to the clinic for cardiovascular and other diseases. AF-219 is a selective, non-narcotic and orally administered P2X3 antagonist. The oversubscribed Series C financing was led by Fidelity Management & Research Company, with participation from other crossover funds Jennison Associates LLC (on behalf of certain clients), New Leaf Ventures, Partner Fund Management, Redmile Group, Tekla Healthcare Investors and Tekla Life Science Investors, in addition to an undisclosed blue chip public investment fund.
Milestone Pharmaceuticals Closes US$17 Million Series B Financing to Complete Phase 2 Clinical Studies for MSP-2017
MONTREAL, QC, June 15, 2015 – Milestone Pharmaceuticals Inc., a clinical stage cardiovascular company in Phase 2, today announced the close of a US$17 million Series B financing. The round was led by Domain Associates and included participation from all of Milestone’s existing investors including Fonds de solidarité FTQ (FSTQ), Pappas Ventures, BDC Capital, GO Capital, and iNovia Capital. The funding will be used to complete Phase 2 clinical development of MSP-2017. In connection with this financing, Domain’s Debra Liebert will join Milestone’s board of directors.
CoLucid Pharmaceuticals Announces Pricing of Initial Public Offering
BURLINGTON, Mass., May 6, 2015 – CoLucid Pharmaceuticals, Inc. ("CoLucid") (CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, announced today the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $10.00 per share.
Envisia Therapeutics to Present at ARVO 2015 Annual Meeting
Research Triangle Park, NC - May 1, 2015 – Envisia Therapeutics today announced that eight posters have been selected for presentation at the Association for Research in Vision and Ophthalmology’s (ARVO) Annual Meeting being held May 3 – 7, 2015 in Denver, Colorado. ARVO is the largest gathering of eye and vision researchers in the world, attracting over 11,000 attendees from more than 75 countries. The theme of the ARVO 2015 Annual Meeting is Powerful Connections: Vision Research and Online Networking.
IlluminOss Medical Appoints Amy Orlick Berman as Vice President of Clinical Affairs
EAST PROVIDENCE, RI, Apr 21, 2015 – IlluminOss Medical, a commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced the appointment of Amy Orlick Berman as the company's vice president of clinical affairs. Berman brings almost two decades of clinical affairs experience and has extensive expertise leading global research programs from inception through product approval. In her new position, she will be responsible for the global clinical trial program at IlluminOss, including the U.S. Lightfix trial towards securing approval for the treatment of impeding and actual fractures of the humerus in patients with metastatic bone disease.
Prior to joining IlluminOss, Berman was at Cordis, Johnson & Johnson for nearly 10 years where she held roles of increasing responsibility and oversaw a number of high-profile clinical research programs in the U.S., Europe and Japan.
